Community carriage of ESBL-producing Escherichia coli and Klebsiella pneumoniae: A cross-sectional study of risk factors and comparative genomics of carriage and clinical isolates

The global prevalence of infections caused by ESBL-producing Enterobacterales (ESBL-E) is increasing and for Escherichia coli observations indicate that this is partly driven by community-onset cases. The ESBL-E population structure in the community is scarcely described and data on risk factors for carriage are conflicting. Here, we report the prevalence and population structure of fecal ESBL-producing E. coli and Klebsiella pneumoniae (ESBL-Ec/Kp) in a general adult population, examine risk factors, and compare carriage isolates with contemporary clinical isolates. Fecal samples obtained from 4999 participants (54% women) [≥]40 years in the seventh survey of the population-based Tromso Study, Norway (2015-2016) were screened for ESBL-Ec/Kp. In addition, we included 118 ESBL-Ec clinical isolates from the Norwegian surveillance program in 2014. All ESBL-producing isolates were whole-genome sequenced. Risk factors associated with carriage were analyzed using multivariable logistic regression. ESBL-Ec gastrointestinal carriage prevalence was 3.3% (95%CI 2.8-3.9%, no sex difference) and 0.08% (0.02-0.20%) for ESBL-Kp. For ESBL-Ec, travel to Asia was the only independent risk factor (AOR 3.47, 95%CI 2.18-5.51). E. coli ST131 was most prevalent in both collections. However, the ST131 proportion was significantly lower in carriage (24%) vs. clinical isolates (58%, p<0.001). Carriage isolates were genetically more diverse with a higher proportion of phylogroup A (26% vs. 5%, p<0.001), indicating that ESBL gene acquisition occurs in a variety of E. coli lineages colonizing the gut. STs commonly related to extra-intestinal infections were more frequent in the clinical isolates also carrying a higher prevalence of antimicrobial resistance, which could indicate clone associated pathogenicity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint
is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 13, 2022. ; https://doi.org/10.1101/2022.11.09.22282110 doi: medRxiv preprint lineage ST73 25,29 among the carriage isolates but found one ST95 25,29 (0.6%) and five isolates 213 of the emerging ST1193 35,36 (3.0%). 214 Using a single nucleotide polymorphism (SNP) cut-off of ≤17 37 , we detected 14 putative 215 clusters (Suppl. Table 5) among 32 of 284 isolates (23 carriage and 9 clinical). Two ST131 216 subclade A clusters contained more than two isolates. One cluster (4-12 SNP differences) 217 consisted of five isolates (four from Tromsø7 and one from NORM 2014) and one with three 218 Tromsø7 isolates (4-7 SNP differences). In addition, twelve clusters represented by nine STs 219 consisted of two isolates each. None of these clusters included isolates from both Tromsø7 and 220 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 13, 2022. ; https://doi.org/10.1101/2022.11.09.22282110 doi: medRxiv preprint The clinical isolates showed an overall higher proportion of phenotypic resistance compared to 235 the carriage isolates ( is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 13, 2022. ; https://doi.org/10.1101/2022.11.09.22282110 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint  is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 13, 2022. ; https://doi.org/10.1101/2022.11.09.22282110 doi: medRxiv preprint been identified as a key contributor to the increase in ESBL prevalence 38 and in a longitudinal 282 study of E. coli bloodstream isolates we identified ST131 to be the single largest contributor to 283 the increase in prevalence of ESBL-Ec in Norway. 25 We also observed the predominance of 284 ST131 in both our collections. However, the proportion is significantly lower in carriage 285 isolates due to lower numbers of the multidrug resistant subclade C2. Moreover, the carriage 286 population had a higher proportion of phylogroup A, associated with asymptomatic intestinal 287 carriage in humans 39, 40  is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 13, 2022. ; https://doi.org/10.1101/2022.11.09.22282110 doi: medRxiv preprint nosocomial spread (NORM 2014 clusters). However, we did not have access to epidemiological 307 data to examine this further. 308 In line with other studies, we found a strong association between ESBL-Ec carriage and travel 309 to Asian regions. [13][14][15]17,22 This supports the current patient screening recommendations for 310 ESBL-producing gram-negative bacteria after hospital stay abroad in the past year before 311 hospital admission in Norway. 43 In contrast to a Swedish and a Dutch study, 15,44 we did not 312 identify travelers' diarrhea as a risk factor for ESBL-Ec carriage. However, our study was not 313 designed to specifically investigate international travelers but rather focused on risk factors in 314 the general adult population. 315 We found no association between ESBL-Ec gut carriage and factors such as hospitalization, 316 antibiotic use, and acid suppressive medication, and conflicting results have been detected in 317 previous studies. 22,45 Hospitalization as a risk factor has mainly been reported from studies 318 investigating patients with ESBL-E infections. 23,46 In line with most studies that assessed risk 319 factors regarding ESBL-E carriage in individuals in the community, we did not identify 320 hospitalization as an independent risk factor. 13,22,44 This may be due to the increased ESBL 321 prevalence not only in hospitals, but also in the community over the last decades and implies 322 that boundaries have become blurred between those two settings. 9,22,47,48 323 The nonsignificant effect of antibiotic use is mainly due to limitations of the drug variable in 324 our study which is based on self-reported data, including topical antibiotics and covers only the 325 last two weeks before self-sampling. As antibiotic use has been found as a risk factor for 326 resistance in many other studies, 14,15,22 we cannot rule out that antibiotic use plays a role in 327 ESBL-E carriage. There are reports identifying an association between the use of gastric acid 328 suppressive medication and intestinal colonization or infections with ESBL-E. 18 However, a Dutch study comparable to ours did not find an association between proton pump 330 inhibitor use and ESBL-E carriage in the overall analysis. 14 331 . CC-BY 4.0 International license It is made available under a perpetuity.
is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 13, 2022. ; Interestingly, we found a possible association between Kp and ESBL-Ec carriage. An 332 association between ESBL-E carriage and vancomycin-resistant enterococci (VRE) has been 333 described previously 7,49 , and also that VRE colonization is significantly associated with Kp 334 colonization among intensive care unit patients. 50  is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 13, 2022. ; https://doi.org/10.1101/2022.11.09.22282110 doi: medRxiv preprint

Study population and design 357
Our study sample was drawn from Tromsø7, the last of seven cross-sectional health surveys 358 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 13, 2022. ; https://doi.org/10.1101/2022.11.09.22282110 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 13, 2022. ; https://doi.org/10.1101/2022.11.09.22282110 doi: medRxiv preprint Italy). In total, 87% (n=5,042) returned a sample either at the second visit, or by mail to the 385 laboratory. 386 All 5,042 fecal samples were screened for the presence of ESBL-producing Ec and Kp via 387 selective culture (see below). All participants completed two self-administered structured 388 questionnaires on socio-demographics, smoking, alcohol use, hospitalization, drug use, and 389 travel abroad. We excluded 13 participants with wrong or missing sample identification 390 number, two retracting consent to medical research, and 28 with incomplete questionnaires for 391 a final study population of 4,999 participants ( Figure 5). We analyzed the association between 392 ESBL-Ec gastrointestinal carriage and different risk factors in 4,996 participants ( Figure 5 and 393 Table 1). Next, we investigated the association between ESBL-Ec carriage and Kp 394 gastrointestinal carriage among 2,972 participants additionally screened for Kp in our previous 395 study, 32 irrespective of resistance ( Figure 5, Supplementary Table 2). 396

Isolation of ESBL-producing E. coli and K. pneumoniae 397
We added 200 µl 85% glycerol to the ESwab tubes upon arrival at the local microbiological 398 laboratory, and stored the samples at -80°C. From the thawed media, 100 µl were plated onto 399 CHROMagar TM ESBL (CHROMagar, Paris, France) and incubated for 48 hours at 37°C. Pink, 400 purple and blue colonies suspected of being ESBL-producing Ec or Klebsiella spp. were 401 identified using mass spectrometry (MALDI-TOF, Bruker Daltonics, Bremen, Germany). The 402 first colony identified as either Ec, K. pneumoniae or K. variicola from each sample was kept 403 and further analyzed. All samples were plated on cysteine lactose electrolyte deficient agar 404 (MAST Group, Bootle, UK) to assess growth of fecal flora and validity of the samples. 405

K. pneumoniae isolation 406
The screening strategy and isolation procedure for Kp, is described in detail elsewhere 32 . 407 Briefly, we plated and screened the fecal samples onto the selective SCAI (Simons citrate agar 408 . CC-BY 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 13, 2022. ; https://doi.org/10.1101/2022.11.09.22282110 doi: medRxiv preprint carriage as an additional explanatory variable (Suppl. Table 2). Explanatory variables were 456 selected with the help of a directed acyclic graph constructed using DAGitty v3.0 (Suppl. Figure  457 3 and 4). 73 All explanatory variables were kept in the fully adjusted models. Multicollinearity 458 between the entered variables was assessed calculating the variance inflation factor (VIF) and 459 tolerance statistic. Multicollinearity was not a problem with VIF>10  is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 13, 2022. ; played no role in study design, data collection, data analysis, data interpretation, or writing of 503 the report. 504

Data Availability 505
Bacterial genome data (raw Illumina reads) are publicly available in NCBI under BioProject 506 PRJEB53319 (NORM 2014 collection) and PRJEB57251 (Tromsø7 collection). This study is 507 based on data owned by a third party (The Tromsø Study, Department of Community Medicine, 508 UiT The Arctic University of Norway). Confidentiality requirements according to Norwegian 509 law prevents sharing of individual patient level data in public repositories. Application of legal 510 basis and exemption from professional secrecy requirements for the use of personal health data 511 in research may be sent to a regional committee for medical and health research ethics 512 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 13, 2022. ; https://doi.org/10.1101/2022.11.09.22282110 doi: medRxiv preprint